levomepromazine

Levomepromazine is a low-potency, first-generation (typical) antipsychotic of the phenothiazine class. It exhibits strong sedative, analgesic, antiemetic, and antihistaminic properties. Its primary mechanism involves antagonism of multiple neurotransmitter receptors in the central nervous system, including dopamine D2 receptors (antipsychotic effect), histamine H1 receptors (sedation), muscarinic acetylcholine receptors (anticholinergic effects), and alpha-adrenergic receptors. Levomepromazine is used in psychiatry for schizophrenia and schizoaffective disorder—especially where sedation is desirable—and widely in palliative care for managing pain, severe agitation or delirium at end-of-life, nausea/vomiting resistant to other treatments, and insomnia[1][2][3][6]. It may also be used as a preoperative sedative or adjunctive agent for terminal pain control[8]. The drug was originally developed by Rhône-Poulenc.

Brand names

Nozinan

Other names

levomepromazine maleatelevomepromazine hydrochloridemethotrimeprazine